Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cell and gene therapy

This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.

Pfizer hedges bets on gene therapy deal

Pfizer hedges bets on gene therapy deal

business model for cell and gene therapies is still being established. ... Vivet Therapeutics’ lead candidate is VTX-801, a gene therapy for Wilson disease, a devastating rare, chronic, and potentially life-threatening liver disorder.

Latest news

  • Oxford Biomedica taps Microsoft to progress gene therapy delivery tech Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

    These new technologies will help advance the next generation of cell and gene delivery approaches, the companies claim. ... Andrew Phillips, Head of Biological Computation at Microsoft, said: "Oxford Biomedica is at the cutting edge of cell and gene

  • FDA chief Scott Gottlieb to step down FDA chief Scott Gottlieb to step down

    The latter included a ‘name and shame’ list of companies which abused regulations to block generic and biosimilar competition.. ... Despite taking on pharma market abuses, Gottlieb’s championing of faster approvals, closer working with the industry

  • Gene Genie Gene Genie

    This aims to find novel, more valid ways of valuing very expensive cell and gene therapies. ... Imagine a thought experiment in which every current and imminent biologic, immunotherapy, rare disease treatment, cell and gene therapy and other advanced new

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    With rival companies such as fellow Swiss group Novartis and Pfizer making big plays in the high-tech cell and gene therapy categories, Roche had been at risk of falling behind. ... The acquisition will inevitably increase expectation of more buyouts in

  • Ipsen buys rare disease group Clementia in $1.3bn deal Ipsen buys rare disease group Clementia in $1.3bn deal

    Through this transaction, we will gain scientific expertise, exceptional talent, and a cornerstone ultra-rare disease drug candidate with rare paediatric disease and breakthrough therapy designations, potential US approval in 2020 ... and gene therapy

More from news
Approximately 29 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    Lonza has worked with 150 cell and gene therapy developers and each project has required a different approach, Hong added. ... As a result, Lonza’s efforts to reduce cell and gene therapy production costs involve logistics, said Hong.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Novartis has a deal with Spark to market Luxturna in Europe,

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Pfizer also has a considerable stake in one of the most exciting emerging areas of innovation, cell and gene therapy. ... It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.

  • Regeneron and Bluebird sign $100m cell therapies deal Regeneron and Bluebird sign $100m cell therapies deal

    Six targets chosen from TCR and other cell therapy platforms. ‘Big biotech’ Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence ... peptides, while Bluebird will contribute

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’ CAR-T ... If you look at how many gene therapy companies there are

More from intelligence
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene

  • Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

    Dr Jones moves to the cell and gene therapy specialist from Swedish biotech Akinion Pharmaceuticals, where he had served as chief executive since January last year. ... He brings a unique combination of international and rare disease expertise, crucial

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Random42 produce over 200 individual digital projects each year and have won over 175 industry awards in their 26-year

  • Training the next generation of biotech leaders

    As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy. ... It brings engineers and people from the life sciences sector into the department to learn about biochemical engineering

  • Life at the end of the Brexit tunnel

    An Advanced Therapies Treatment Centre to develop cell and gene therapies. ... Expansion of the Cell and Gene Therapy Manufacturing Centre in Stevenage.

  • Healthcare in the Digital Age

    Drug discovery is buoyant and innovative technology is pushing medicine forward at unprecedented speed. ... Exciting developments in immunotherapy and oncology, and huge strides in gene and stem-cell therapy are matched by powerhouse collaborations

  • Blue Latitude Health

    Blue Latitude Health speaks to Dr Ivan Wall, Reader in Cell &Gene Therapy Bioprocessing at University College London, to find out about the future of cell and gene therapy, the impact ... Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Quick links

Infographics

Multimedia